Vitamin E analogues: A new class of inducers of apoptosis with selective anti-cancer effects

Jiri Neuzil, Marco Tomasetti, Albert S. Mellick, Renata Alleva, Brian A. Salvatore, Marc Birringer, Marc W. Fariss

Research output: Contribution to journalArticlepeer-review

Abstract

In spite of unrelenting effort, the net incidence of neoplastic diseases appears not to have been curbed. While some types of cancer have been suppressed significantly, others are either stagnating or on the increase. Therefore, the need for a cure is imperative, in particularly a drug or combination of drugs that would be selective for malignant cells, i.e. with as low secondary toxicity as possible. Recent data strongly suggest that analogues of vitamin E, epitomised by the most studied α-tocopheryl succinate (α-TOS), may meet the need for the coveted drugs with a selective anti-neoplastic effect. The reasons for this optimism are reviewed in this article.

Original languageEnglish
Pages (from-to)355-372
Number of pages18
JournalCurrent Cancer Drug Targets
Volume4
Issue number4
DOIs
Publication statusPublished - Jun 2004

ASJC Scopus subject areas

  • Cancer Research
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Vitamin E analogues: A new class of inducers of apoptosis with selective anti-cancer effects'. Together they form a unique fingerprint.

Cite this